Michael Doe
HPAPI and CytotoxicDrugs Manufacturing by Roots Analysis... more
What's New
-
Michael Doe wrote a new blog entry:
Over time, important advances in diagnosis and the development of versatile treatment options have translated into tangible improvements in the overall survival of lung cancer patients; several targeted therapies are being developed against squamous NSCLC...- December 30, 2021
- Michael Doe wrote a new blog entry: Vascular disrupting agents (VDAs) are the novel oncology drugs being developed to more specifically combat complex, life threatening cancer indications
London
Roots Analysis has announced the addition of “Vascular Disrupting Agents... - Michael Doe wrote a new blog entry: Rising prevalence of skin disorders is expected to promote the adoption of light activated therapies, making it one of the relatively faster growing segments in this industry
Roots Analysis has announced the addition of “Light Activated The... - Michael Doe wrote a new blog entry: The exact cause of this rare disorder, which affects 5-17 in 100,000 people, is unknown; however, a complex interplay between different risk factors, including age, genetics and environment, is likely to contribute to the onset of this rare tauopathy
&nb... - Michael Doe wrote a new blog entry: Several novel and innovative therapeutic approaches, both small molecule and biologics, are being currently investigated at various phases of development in order to avoid the beginning of disease-induced attacks and other long-term effects of porphyria
... - Michael Doe wrote a new blog entry: Light activated therapies are considered to be a transformative approach owing to their capability to eradicate diseased cells from the body with minimal side effects; presenting lucrative opportunities for players engaged in the development of such produ...
- Michael Doe wrote a new blog entry: During our research, we came across over 43 companies that are presently engaged in the development of DDR targeting therapeutics. There has been a significant increase in the number of developers that have been established in this domain post-2008. In fa...
- Michael Doe wrote a new blog entry: A major increase in the number of different types of solutions for treating various indications, has been observed in the past two years. In fact, from June 2018 to in June 2020, there has been increase of 22 approved and 106 marketed digital therapeutic ...
- Michael Doe wrote a new blog entry: The primary purpose of this analysis was to develop a deeper understanding of the overall strength of the contract service providers involved in this field. It allows companies to compare their existing capabilities within their respective peer groups and...
- Michael Doe wrote a new blog entry: The exact cause of this rare disorder, which affects 5-17 in 100,000 people, is unknown; however, a complex interplay between different risk factors, including age, genetics and environment, is likely to contribute to the onset of this rare tauopathy
&nb... - Michael Doe wrote a new blog entry: Several novel and innovative therapeutic approaches, both small molecule and biologics, are being currently investigated at various phases of development in order to avoid the beginning of disease-induced attacks and other long-term effects of porphyria
... - Michael Doe wrote a new blog entry: Light activated therapies are considered to be a transformative approach owing to their capability to eradicate diseased cells from the body with minimal side effects; presenting lucrative opportunities for players engaged in the development of such produ...
- Michael Doe wrote a new blog entry: Owing to reasons, such as a booming economy and availability of skilled labor, outsourcing to Asian CMOs, primarily in China, is considered an attractive business model to pharmaceutical developers / sponsors, across the world
Roots Analysis is p... - Michael Doe wrote a new blog entry: The recent approval of Aduhelm™, an amyloid beta-directed antibody has led to players seeking approval for similar therapies; various interventions are being evaluated for the treatment / management of the inherently complex neurodegenerative diseas...
- Michael Doe wrote a new blog entry: Polycystic ovary syndrome affects 1 in 10 women of childbearing age. The exact cause of the condition is unknown; however, obesity, high levels of inflammation and insulin resistance are the common risk factors
London
Roots Analysis has ... - Michael Doe wrote a new blog entry: Driven by the growing complexity of modern pharmacological interventions, industry stakeholders have developed container-closures systems using more versatile materials; in this context, elastomers have demonstrated significant potential
Roots An... - Michael Doe wrote a new blog entry: To order this detailed 245+ page report, please visit this - https://www.rootsanalysis.com/reports/collaborative-robots-market.html
Key Inclusions
An overview of the current market landscape of cobots, providing information on the market avail... - Michael Doe wrote a new blog entry: Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing
Roots A... - Michael Doe wrote a new blog entry: Benefits offered by microbial biomanufacturing, such as low production costs and faster development timelines, have led many innovators to adopt these platforms for next generation biologics, offering lucrative opportunities for CMOs / CDMOs
Root... - Michael Doe wrote a new blog entry: Given the recent developments in healthcare, supporting safety and efficacy of peptide and affiliated macrocycle drugs, the industry is presently witnessing an increase in discovery and development initiatives related to such therapeutic modalities.
&nbs... - Michael Doe wrote a new blog entry:
The recent approval of first RNAi therapeutic, ONPATTROTM, has caused a surge in interest of the industry / non-industry players in upcoming field of pharmacological research... more - Michael Doe wrote a new blog entry: Advances in screening technologies have enabled the identification of interactive gene combinations, enabling the development of lead candidates that leverage the principle of synthetic lethality for cancer treatment
To order this 485+ page repor... - Michael Doe wrote a new blog entry: To order this 330+ page report, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
Key Inclusions
A detailed assessment of the current market landscape of targeted protein degradation-based the... - Michael Doe wrote a new blog entry: Roots Analysis has done a detailed study on Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics, covering key aspects of the industry’s evolution and identifying potent...
- Michael Doe wrote a new blog entry: Roots Analysis has done a detailed study on Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 370+ page re... - Michael Doe wrote a new blog entry:
Roots Analysis has done a detailed study on Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030, covering key aspects of the industry and identifying key future growth opportunities.
To order this 370+ page repor... - Michael Doe wrote a new blog entry: Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing
Roots A... - Michael Doe wrote a new blog entry: The increasing medical diagnostic imaging burden has compelled industry players to develop advanced handheld ultrasound scanners that will enable physicians to accurately visualize all major organ systems for diagnostic purposes
Roots Analysis h... - Michael Doe wrote a new blog entry: Manufacturing highly potent drug products is technically and financially demanding; as a result, drug manufacturers are becoming increasingly reliant on contract service providers
Roots Analysis is pleased to announce the publication of its recen... - Michael Doe wrote a new blog entry: To order this 300+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html
Key Inclusions
A detailed review of the current status of the market with respect to oligonucleotide man... - Michael Doe wrote a new blog entry: Given the complex R&D protocols and the increasing demand for clinical evidence of therapeutic benefit, there seems to be a lucrative opportunity for contract research providers engaged in the medical devices’ domain. In fact, since 2000, 150 new CR...
- Michael Doe wrote a new blog entry: With increasing cases of drug failure, due to problems associated with pharmacokinetic profiles of candidate therapies, absorption, distribution, metabolism and excretion (ADME) properties and inherent toxicity, industry players are actively looking for m...
- Michael Doe wrote a new blog entry: To order this 510+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/cell-therapies-supply-chain/260.html
Key Inclusions
A detailed assessment of the current market landscape, featuring a comprehensive list o... - Michael Doe wrote a new blog entry: Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers
Roots Analy... - Michael Doe wrote a new blog entry: Report link - https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html\
Key... more - Michael Doe wrote a new blog entry: To order this 170+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html
Key Inclusions
A detailed review of the overall landscape of fragment-based drug discovery library a... - Michael Doe wrote a new blog entry: To order this 250+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/peptide-therapeutics-manufacturing/305.html
Key Inclusions
A detailed review of the overall landscape of companies offering contract serv... - Michael Doe wrote a new blog entry: Over time, many pharma companies have begun incorporating augmented reality (AR) and virtual reality (VR) features, in order to offer an experiential and interactive dimension to their educational / marketing content
Roots Analysis has done a det... - Michael Doe wrote a new blog entry: The surge in demand for COVID-19 vaccines has presented lucrative opportunities for both innovators and contract service providers having continuous and semi-continuous manufacturing capabilities for biointensification
London
Roots Analy... - Michael Doe wrote a new blog entry: Driven by the potential to confer safe and sustained therapeutic effects for clinical conditions unique to women, the non-hormonal therapies pipeline is growing, featuring candidates having improved risk profiles and lesser side effects
... - Michael Doe wrote a new blog entry: The rapidly growing pipeline of recombinant glycoprotein therapeutics, especially the glycoengineered variants of COVID-19 drugs, has presented lucrative opportunities for contract service providers with expertise in glycoconjugate / glycan analysis
&nbs... - Michael Doe wrote a new blog entry: To order this detailed 300+ page report, please visit this- https://www.rootsanalysis.com/reports/view_document/medical-device-labels-manufacturing-market-2019-2030/272.html
Key Inclusions
A detailed review of the overall landscape of companie... - Michael Doe wrote a new blog entry: To order this detailed 350+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Key Inclusions
A detailed assessment of the current market landscape, including information ... - Michael Doe wrote a new blog entry:
To order this detailed 180+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/peptides-and-macrocycle-discovery/300.html
Key... more - Michael Doe wrote a new blog entry: The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), ...
- Michael Doe wrote a new blog entry: Driven by the potential to confer sustained therapeutic effects and thereby, facilitate prolonged periods of remission, TIL-based therapies have received significant financial support, and promising leads are poised to soon achieve blockbuster status
&nb... - Michael Doe HPAPI and Cytotoxic
Drugs Manufacturing by Roots Analysis... more -
- Michael Doe The High Energy /
Hazardous Chemistry-based API manufacturing services market is estimated to
be worth USD 29 billion in 2030, predicts Roots... more - Michael Doe The contract fill /
finish services market for biologics is anticipated to be worth USD 4.2
billion by... more
